Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to $6.1 million.

  • Sunshine Biopharma's Accounts Payables rose 4763.27% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 4763.27%. This contributed to the annual value of $5.5 million for FY2024, which is 11439.4% up from last year.
  • Per Sunshine Biopharma's latest filing, its Accounts Payables stood at $6.1 million for Q3 2025, which was up 4763.27% from $4.8 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Accounts Payables ranged from a high of $6.1 million in Q3 2025 and a low of $42942.0 during Q4 2021
  • Moreover, its 5-year median value for Accounts Payables was $2.6 million (2023), whereas its average is $2.5 million.
  • Over the last 5 years, Sunshine Biopharma's Accounts Payables had its largest YoY gain of 642693.63% in 2022, and its largest YoY loss of 3589.7% in 2022.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Accounts Payables stood at $42942.0 in 2021, then skyrocketed by 6426.94% to $2.8 million in 2022, then dropped by 7.75% to $2.6 million in 2023, then skyrocketed by 114.39% to $5.5 million in 2024, then increased by 10.72% to $6.1 million in 2025.
  • Its Accounts Payables stands at $6.1 million for Q3 2025, versus $4.8 million for Q2 2025 and $5.0 million for Q1 2025.